Suppr超能文献

肾移植前后的心血管风险评估

Cardiovascular risk assessment before and after kidney transplantation.

作者信息

Glicklich Daniel, Vohra Parag

机构信息

From the *Department of Medicine, Division of Nephrology, New York Medical College, Valhalla, NY; and †Westchester Medical Center, Kidney Transplant Service, Valhalla, NY.

出版信息

Cardiol Rev. 2014 Jul-Aug;22(4):153-62. doi: 10.1097/CRD.0000000000000012.

Abstract

Cardiovascular disease (CVD) is the leading cause of death in dialysis patients and the most common cause of death and allograft loss among kidney transplant recipients. End-stage renal disease (ESRD) is associated with an increased incidence and prevalence of a wide range of CVDs including coronary artery disease, stroke, congestive heart failure, atrial fibrillation, sudden cardiac death, pulmonary hypertension, and valvular heart disease. CVD risk factors are very common in patients with ESRD, and most patients have multiple risk factors. Kidney transplantation is the treatment of choice for patients with ESRD, as a successful transplant improves longevity and quality of life, primarily by decreasing the incidence and severity of CVD. Correction of the uremic state and improved glomerular filtration rate seem to be the major mechanism of this benefit. Transplant candidates should undergo cardiovascular assessment, usually echocardiography and exercise stress testing, and may require formal cardiology consultation. Higher risk candidates, including those aged >50 years, hypertension, diabetes, established coronary artery disease or peripheral vascular disease, left ventricular hypertrophy, and dialysis duration >1 year, should have repeat cardiovascular assessment every 1-2 years. Transplant candidates and recipients should have individualized treatment for CVD and risk factors such as hypertension, diabetes, hyperlipidemia, and obesity. Special consideration should be given for statin therapy, as its use is associated with decreased cardiovascular death in dialysis and transplant patients. Prospective randomized, controlled trials are needed to determine the optimal approach to diagnosis and treat CVD in the transplant candidate and recipient population.

摘要

心血管疾病(CVD)是透析患者死亡的主要原因,也是肾移植受者死亡和移植肾失功的最常见原因。终末期肾病(ESRD)与多种心血管疾病的发病率和患病率增加相关,这些疾病包括冠状动脉疾病、中风、充血性心力衰竭、心房颤动、心源性猝死、肺动脉高压和心脏瓣膜病。心血管疾病危险因素在ESRD患者中非常常见,大多数患者有多种危险因素。肾移植是ESRD患者的首选治疗方法,因为成功的移植主要通过降低心血管疾病的发病率和严重程度来提高患者的寿命和生活质量。纠正尿毒症状态和提高肾小球滤过率似乎是这种益处的主要机制。移植候选者应接受心血管评估,通常采用超声心动图和运动负荷试验,可能还需要正式的心脏病学咨询。高风险候选者,包括年龄>50岁、高血压、糖尿病、已确诊的冠状动脉疾病或外周血管疾病、左心室肥厚以及透析时间>1年的患者,应每1 - 2年进行一次重复心血管评估。移植候选者和受者应针对心血管疾病以及高血压、糖尿病、高脂血症和肥胖等危险因素进行个体化治疗。他汀类药物治疗应给予特别考虑,因为其使用与透析患者和移植患者心血管死亡风险降低相关。需要进行前瞻性随机对照试验,以确定在移植候选者和受者群体中诊断和治疗心血管疾病的最佳方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验